Barry A. Labinger
Chief Executive Officer at Gilboa Therapeutics Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Yaron Carmi | M | - |
Gilboa Therapeutics Ltd.
 Gilboa Therapeutics Ltd. BiotechnologyHealth Technology Gilboa Therapeutics Ltd. is a preclinical-stage biopharmaceutical company located in Israel. The Israeli company is focused on developing novel and high-impact, next-generation cancer immunotherapies that harness the power of a patient's own immune system to treat cancer, improve outcomes, and save lives. Gilboa's proprietary technology, solidt, is an engineered cell therapy that targets multiple different tumor types and is intended to be used in combination with a wide range of antigen-specific antibodies. The company is driven by a sense of urgency to discover, develop, and rapidly bring their game-changing new therapeutics to cancer patients in need, significantly improving outcomes and saving lives. | - |
| Omri Amirav-Drory | M | - |
Gilboa Therapeutics Ltd.
Gilboa Therapeutics Ltd. BiotechnologyHealth Technology Gilboa Therapeutics Ltd. is a preclinical-stage biopharmaceutical company located in Israel. The Israeli company is focused on developing novel and high-impact, next-generation cancer immunotherapies that harness the power of a patient's own immune system to treat cancer, improve outcomes, and save lives. Gilboa's proprietary technology, solidt, is an engineered cell therapy that targets multiple different tumor types and is intended to be used in combination with a wide range of antigen-specific antibodies. The company is driven by a sense of urgency to discover, develop, and rapidly bring their game-changing new therapeutics to cancer patients in need, significantly improving outcomes and saving lives. | 3 years |
| James Wooldridge | M | 58 | 5 years | |
| Theresa Reinseth | F | 51 | 19 years | |
| Kleem Chaudhary | M | 48 | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Giovanni Caforio | M | 59 | 24 years | |
| Lamberto Andreotti | M | 73 | 19 years | |
| Stephen Worland | M | 66 |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | 10 years |
| Alan Fuhrman | M | 67 | 3 years | |
| Stelios Papadopoulos | M | 75 |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | 19 years |
| Kleanthis Xanthopoulos | M | 66 |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | 19 years |
| Anatolio Cruz | M | 65 | 3 years | |
| Robert Morrison | M | 81 | 11 years | |
| Vance D. Coffman | M | 79 | 20 years | |
| Robert Dolski | M | 54 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 5 years |
| Colin Goddard | M | 64 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 2 years |
| George Morrow | M | 72 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 1 years |
| Brian Daniels | M | 65 | 14 years | |
| Michael Eskew | M | 74 | 21 years | |
| David Southwell | M | 63 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 4 years |
| Leif Valdemar Johansson | M | 73 | 13 years | |
| Lewis B. Campbell | M | 77 | 18 years | |
| Craig Parker | M | 63 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 4 years |
| Katherine Strei | F | 62 | 7 years | |
| John E. Elicker | M | 64 | 20 years | |
| Gregory Norden | M | 66 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 1 years |
| Peter Colabuono | M | - | 3 years | |
| Kevin P. McRaith | M | - |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | - |
| Keith Flaherty | M | 53 | 3 years | |
| Fouad Namouni | M | 55 | 21 years | |
| Nilesh Kumar | M | 47 | 1 years | |
| Paul Keel | M | 54 | 16 years | |
| Chuck Yon | M | - | 6 years | |
| Laurie Glimcher | M | 72 | 20 years | |
| Gerald Bruce | M | 68 | 8 years | |
| Peggy Phillips | F | 70 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 6 years |
| Charles Sigal | M | 72 | 16 years | |
| Mark Foletta | M | 63 |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | 6 years |
| James L. Freddo | M | 69 |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | 5 years |
| Jerome Hauer | M | 72 | 8 years | |
| Maxine Gowen | M | 66 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 4 years |
| Jay Ihlenfeld | M | 72 | 8 years | |
| Marios Fotiadis | M | 51 |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | 9 years |
| Susan Holmes | F | - | 3 years | |
| Michael Giordano | M | 66 | 18 years | |
| Robert W. Morrissey | M | 66 | 6 years | |
| James T. Crines | M | 64 | 2 years | |
| Ning Yan | M | - | 7 years | |
| Fu-Min Su | M | - | 6 years | |
| Gerald Crabtree | M | 83 | 7 years | |
| Cheryl Capps | F | 62 | 13 years | |
| Steven R. Arikian | M | 65 | 2 years | |
| Elliott Levy | M | 64 | 17 years | |
| Douglas Hay | M | - | 6 years | |
| Miguel Forte | M | 63 | 5 years | |
| Elizabeth Yamashita | F | - | 6 years | |
| Emmanuel Blin | M | 54 | - | |
| Arturo O. Araya | M | 53 | 3 years | |
| Charles Conway | M | 62 | 17 years | |
| Kimberly Gentile | F | 56 | 14 years | |
| John H. Lawrence | M | - | 18 years | |
| Adam Dubow | M | 57 | - | |
| Georgia Keresty | M | 62 | 4 years | |
| Kevin McManus | M | - | 9 years | |
| Gregg L. Bienstock | M | 59 | 1 years | |
| Yadagiri R Pendri | M | 68 | 7 years | |
| Chris Keller | M | - | 3 years | |
| Donald Handley | M | - | 3 years | |
| Larry K. Benedict | M | 63 | 7 years | |
| Erik Harris | M | 54 | 2 years | |
| Kenneth F. Anderson | M | - | 17 years | |
| Luigi Lenaz | M | 83 | 19 years | |
| Anne N. Nielsen | F | 63 | - | |
| Helen Torley | M | 61 | 5 years | |
| John D. Macomber | M | 96 | 5 years | |
| Phillip John Brancazio | M | 71 | 23 years | |
| Daniel M. Bollag | M | 63 | 2 years | |
| Kevin Rooney | M | 58 | 6 years | |
| Timothy McNamara | M | 67 | 9 years | |
| Nicole Onetto | M | 71 | 6 years | |
| Louis T. DiFazio | M | 86 | 7 years | |
| Mark E. McGovern | M | 70 | 11 years | |
| David E. Martin | M | 57 | 2 years | |
| Jane A. Kramer | F | 68 | 11 years | |
| Richard J. White | M | 82 | 12 years | |
| Patricia Bellinger | F | 63 | 5 years | |
| Joseph C. Caldarella | M | 68 | 20 years | |
| Peter S. Linsley | M | 72 | 14 years | |
| Joachim von Roy | M | 79 | - | |
| Michael Tardugno | M | 73 | 2 years | |
| James R. Ellinghausen | M | 65 | 8 years | |
| Fabio M. Benedetti | M | 58 | 3 years | |
| Kenneth E. Lebioda | M | - | 5 years | |
| Brian Crynes | M | 77 | 3 years | |
| Robert Francis Doman | M | 74 | 8 years | |
| Robert Peach | M | 68 | 9 years | |
| Beth Anne Piper | M | - | 4 years | |
| Mark Trudeau | M | 62 | 11 years | |
| Ellen Futter | F | 74 | 6 years | |
| Benjamin Winograd | M | 63 | 9 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 98.00% |
| Israel | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Barry A. Labinger
- Personal Network
